573 related articles for article (PubMed ID: 25549705)
1. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
3. Immune therapy for kidney cancer: a second dawn?
McDermott DF; Atkins MB
Semin Oncol; 2013 Aug; 40(4):492-8. PubMed ID: 23972713
[TBL] [Abstract][Full Text] [Related]
4. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
6. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
Bailey A; McDermott DF
Cancer J; 2013; 19(4):348-52. PubMed ID: 23867517
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
10. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.
Zibelman M; Ghatalia P; Geynisman DM; Plimack ER
Immunotherapy; 2016 Jun; 8(7):785-98. PubMed ID: 27349978
[TBL] [Abstract][Full Text] [Related]
12. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade in renal cell cancer.
Beckermann KE; Johnson DB; Sosman JA
Expert Rev Clin Immunol; 2017 Jan; 13(1):77-84. PubMed ID: 27426025
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
16. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy for Renal Cell Carcinoma].
Büchler T
Klin Onkol; 2015; 28 Suppl 4():4S64-8. PubMed ID: 26647891
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
19. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
20. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
